Skip to main content
Fig. 3 | Respiratory Research

Fig. 3

From: The effects of benralizumab on airway geometry and dynamics in severe eosinophilic asthma: a single-arm study design exploring a functional respiratory imaging approach

Fig. 3

*All patients had BEC ≥ 300 cells/µL, documented high-dose ICS-LABA ≥ 12 months, and pre-BD FVC < 65% predicted. BD, bronchodilator; BEC, blood eosinophil count; FVC, forced vital capacity; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; Q4W, every 4 weeks; Q8W, every 8 weeks

Time to first exacerbation in the SIROCCO (A) and CALIMA (B) trials * [20, 24].

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us